16 groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023

On Friday, 3 August 2018, 16 groups sent an open letter to WHO Director-General, Dr Tedros Adhanom Ghebreyesus expressing views on the proposed WHO Roadmap on Access to Medicines and Vaccines 2019-2023. The letter requested the Director-General to strengthen activities… Continue Reading

As Pandemic Preparedness bill clears House committee, effort to include antibiotics transferable exclusivity extension fails

On July 18, 2018, the U.S. House Energy and Commerce committee gave its approval to HR 6378, the Pandemic and All-Hazards Preparedness Act, known as PAHPA. During the mark up, Reps. John Shimkus (R-IL) and Tony Cárdenas (D-CA) proposed attaching… Continue Reading

WHO publishes Meeting Report of the Informal Advisory Group on the Availability and Affordability of Cancer Medicines

In May 2017, the 70th World Health Assembly passed a cancer resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach). At the time KEI provided the following commentary on the cancer resolution: On Tuesday, May 30,… Continue Reading

WHA71: KEI intervention on the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018

At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018. 11.7 Preparation for… Continue Reading

WHA71: KEI intervention on Global strategy and plan of action on public health, innovation and intellectual property

At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property: 11.6 Global strategy and plan of action on public health, innovation and intellectual… Continue Reading

Delinkage

There is a specialized web page on delinkage here: http://delinkage.org De-linkage can be defined in the negative, by saying that the R&D funding should not be tied to the price of the product. Progressive de-linkage means that governments implement reforms… Continue Reading

Negotiations on R&D funding agreements

1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading

EB142: KEI statement on WHO’s decision on the Global strategy and plan of action on public health, innovation and intellectual property

After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading